NCT06780059 is a clinical trial of Adjuvant Radiotherapy in Radiotherapy, Adjuvant, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Who is sponsoring NCT06780059?

NCT06780059 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

What drugs are being tested in NCT06780059?

Interventions in NCT06780059: Adjuvant Radiotherapy, R0 resection.

What condition does NCT06780059 study?

NCT06780059 studies Radiotherapy, Adjuvant, Phyllodes Breast Tumor, Prognosis.

Is NCT06780059 still recruiting?

NCT06780059 is currently completed. Last updated 17 January 2025.

Last reviewed 2025-01-17 · How we verify

NCT06780059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection

Completed Last updated 17 January 2025

What this trial tests

trial testing Adjuvant Radiotherapy in Radiotherapy, Adjuvant in 480 participants. Completed in 2 January 2025.

Timeline

30 December 2024

Primary endpoint
2 January 2025

2 January 2025

Quick facts

Lead sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	480
Start date	30 December 2024
Primary completion	2 January 2025
Estimated completion	2 January 2025
Sites	3 locations across China

Drugs / interventions tested

Adjuvant Radiotherapy
R0 resection

Conditions studied

Radiotherapy, Adjuvant — all drugs for Radiotherapy, Adjuvant →
Phyllodes Breast Tumor — all drugs for Phyllodes Breast Tumor →
Prognosis — all drugs for Prognosis →

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Eligibility, female only, with Radiotherapy, Adjuvant or Phyllodes Breast Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Breast phyllodes tumors (PT) are rare fibroepithelial neoplasms originating from stromal tissue and account for less than 1% of all breast tumors. The World Health Organization (WHO) classifies PT into benign, borderline, and malignant subtypes based on pathological features such as mitotic activity, cellular atypia, tumor margin invasion, and stromal composition 1. The presence of malignant heterologous elements characterizes the tumor as malignant 2. Surgery is the primary treatment. However, even after R0 resection, borderline phyllodes tumors (BoPT) and malignant phyllodes tumors (MPT) patients remain face a high risk of local recurrence, with rates of 15%-20% and 25%-30%, respectively. Moreover, metastases occur almost merely in MPT, with a distant metastasis rate reaching 22%. Adjuvant radiotherapy has attracted attention for its potential to improve local control and reduce recurrence, but the role after R0 resection in PT patients remains unclear. Radiotherapy significantly reduces local recurrence rates in BoPT and MPT but shows no substantial benefit in benign cases. However, a meta-analysis by Yu et al. found that this effect is limited to MPT. Additionally, the effect of radiotherapy on survival rates in PT remains controversial. Most existing studies are retrospective and face limitations such as small sample sizes. The rarity of PT and conflicting evidence of impact of radiotherapy necessitate further study. While prospective trials are difficult due to limited cases, well-designed retrospective studies can offer valuable insights. In this study, the investigators also analyzed prognostic factors and identified subgroups to provide a clinical reference for the application of postoperative radiotherapy in BoPT and MPT patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of radiotherapy in borderline and malignant phyllodes tumors after R0 resection: a propensity score analysis.
Ma B, Li X, Zhuang Z, Han M, et al · · 2025 · PMID 41179117 · DOI 10.1177/17588359251387556

Verify or expand the search:

Other trials of Adjuvant Radiotherapy

Trials testing the same drug.

NCT07524452 — Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, · Phase 3 · recruiting
NCT07371234 — Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck · Phase 2 · recruiting
NCT06897488 — EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: · Phase 2 · recruiting
NCT06133465 — Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management · completed
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Other recruiting trials for Radiotherapy, Adjuvant

Currently open trials in the same condition.

NCT07186621 — Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC · Phase 3 · recruiting
NCT07116213 — Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer · NA · recruiting
NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting
NCT06826885 — Safety and Efficacy of IMPT or IMRT for Breast Cancer · recruiting
NCT03239626 — Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer · NA · active not recruiting

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07168083 — Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression · not yet recruiting
NCT07413497 — A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in · not yet recruiting
NCT07461077 — Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer · NA · not yet recruiting
NCT07533526 — Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous I · NA · not yet recruiting
NCT07408648 — A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06780059 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Last refreshed: 17 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06780059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing